IBA and Framatome Form Joint Venture to Scale Astatine-211 Production for Cancer Therapies
Event summary
- IBA and Framatome have established a joint venture, Ekalia, to industrialize Astatine-211 production for targeted cancer therapies.
- The first production site is planned in Nantes, France, with operations expected to begin in 2028.
- Ekalia aims to deploy additional production sites across Europe and North America.
- IBA’s Cyclone® iKure cyclotron and Framatome’s nuclear industrial expertise will drive the initiative.
The big picture
The partnership between IBA and Framatome addresses a critical gap in the nuclear medicine sector by industrializing the production of Astatine-211, a promising alpha-emitting radioisotope for targeted cancer therapies. This initiative aligns with broader trends in precision medicine and the increasing demand for scalable, reliable supply chains in the healthcare industry. The success of Ekalia could set new benchmarks for theranostics, reinforcing the commitment to innovation and improving global access to life-saving treatments.
What we're watching
- Production Scale
- The pace at which Ekalia can establish and operationalize additional production sites will determine the availability of Astatine-211 for cancer therapies.
- Market Expansion
- Whether the joint venture can successfully deploy production sites across Europe and North America will shape the global supply of this critical radioisotope.
- Regulatory Dynamics
- How regulatory frameworks in different regions will impact the deployment and operation of Astatine-211 production sites.
Related topics